GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (XTAE:KMDA) » Definitions » Cyclically Adjusted FCF per Share

Kamada (XTAE:KMDA) Cyclically Adjusted FCF per Share : ₪0.61 (As of Mar. 2025)


View and export this data going back to 2005. Start your Free Trial

What is Kamada Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Kamada's adjusted free cash flow per share for the three months ended in Mar. 2025 was ₪-0.123. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ₪0.61 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Kamada's average Cyclically Adjusted FCF Growth Rate was 238.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-05-29), Kamada's current stock price is ₪24.10. Kamada's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was ₪0.61. Kamada's Cyclically Adjusted Price-to-FCF of today is 39.51.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Kamada was 2005.00. The lowest was 36.67. And the median was 107.56.


Kamada Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Kamada's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Cyclically Adjusted FCF per Share Chart

Kamada Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.24 0.03 0.16 0.58

Kamada Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.32 0.54 0.58 0.61

Competitive Comparison of Kamada's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kamada's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Kamada's Cyclically Adjusted Price-to-FCF falls into.


;
;

Kamada Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kamada's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.123/134.9266*134.9266
=-0.123

Current CPI (Mar. 2025) = 134.9266.

Kamada Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.603 100.684 -0.808
201509 -0.146 100.392 -0.196
201512 -0.592 99.792 -0.800
201603 0.606 100.470 0.814
201606 -0.624 101.688 -0.828
201609 -0.213 101.861 -0.282
201612 0.157 101.863 0.208
201703 0.026 102.862 0.034
201706 -0.142 103.349 -0.185
201709 -0.196 104.136 -0.254
201712 0.188 104.011 0.244
201803 0.435 105.290 0.557
201806 -0.306 106.317 -0.388
201809 0.045 106.507 0.057
201812 0.515 105.998 0.656
201903 0.493 107.251 0.620
201906 0.541 108.070 0.675
201909 0.453 108.329 0.564
201912 0.661 108.420 0.823
202003 -0.228 108.902 -0.282
202006 0.980 108.767 1.216
202009 -0.297 109.815 -0.365
202012 0.822 109.897 1.009
202103 0.155 111.754 0.187
202106 -0.346 114.631 -0.407
202109 -0.349 115.734 -0.407
202112 -0.493 117.630 -0.565
202203 0.381 121.301 0.424
202206 0.823 125.017 0.888
202209 0.281 125.227 0.303
202212 0.424 125.222 0.457
202303 -0.308 127.348 -0.326
202306 0.060 128.729 0.063
202309 -0.053 129.860 -0.055
202312 0.150 129.419 0.156
202403 -0.099 131.776 -0.101
202406 0.695 132.554 0.707
202409 1.278 133.029 1.296
202412 0.425 133.157 0.431
202503 -0.123 134.927 -0.123

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Kamada  (XTAE:KMDA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Kamada's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=24.10/0.61
=39.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Kamada was 2005.00. The lowest was 36.67. And the median was 107.56.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Kamada Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Kamada's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kamada Business Description

Industry
Traded in Other Exchanges
Address
2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.